REGENXBIO Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

REGENXBIO wird ein jährliches Gewinn- und Umsatzwachstum von 30.5% bzw. 36.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 47% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -3.9% betragen.

Wichtige Informationen

30.5%

Wachstumsrate der Gewinne

47.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.2%
Wachstumsrate der Einnahmen	36.4%
Zukünftige Eigenkapitalrendite	-3.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	07 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 04

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

May 11

Recent updates

Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?

Sep 12

Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder

Aug 06

REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 04

Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price

Jul 26

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

Jun 11

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

May 11

REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Apr 25

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

Mar 11

Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Mar 07

Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Mar 05

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 02

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 11

Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

May 08

Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be

Mar 05

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:RGNX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	233	-133	N/A	N/A	6
12/31/2025	282	-86	N/A	N/A	10
12/31/2024	92	-226	N/A	N/A	9
6/30/2024	89	-241	-195	-191	N/A
3/31/2024	87	-260	-199	-193	N/A
12/31/2023	90	-263	-228	-218	N/A
9/30/2023	99	-261	-231	-217	N/A
6/30/2023	97	-274	-236	-218	N/A
3/31/2023	110	-270	-257	-232	N/A
12/31/2022	113	-280	-238	-207	N/A
9/30/2022	480	74	134	173	N/A
6/30/2022	484	91	128	181	N/A
3/31/2022	474	101	143	207	N/A
12/31/2021	470	128	135	219	N/A
9/30/2021	93	-212	-166	-83	N/A
6/30/2021	161	-145	-147	-77	N/A
3/31/2021	156	-121	-116	-63	N/A
12/31/2020	155	-111	-81	-54	N/A
9/30/2020	145	-91	-134	-119	N/A
6/30/2020	61	-135	-123	-112	N/A
3/31/2020	52	-103	-128	-114	N/A
12/31/2019	35	-95	-119	-108	N/A
9/30/2019	64	-64	-102	-86	N/A
6/30/2019	55	-49	-93	-77	N/A
3/31/2019	87	-37	4	17	N/A
12/31/2018	219	100	91	105	N/A
9/30/2018	180	80	84	95	N/A
6/30/2018	176	78	90	97	N/A
3/31/2018	142	53	N/A	18	N/A
12/31/2017	10	-73	N/A	-58	N/A
9/30/2017	10	-77	N/A	-65	N/A
6/30/2017	9	-74	N/A	-59	N/A
3/31/2017	5	-74	N/A	-58	N/A
12/31/2016	5	-63	N/A	-49	N/A
9/30/2016	7	-49	N/A	-33	N/A
6/30/2016	8	-38	N/A	-29	N/A
3/31/2016	7	-32	N/A	-29	N/A
12/31/2015	8	-24	N/A	-23	N/A
9/30/2015	4	-21	N/A	-18	N/A
6/30/2015	4	-16	N/A	-13	N/A
3/31/2015	4	-8	N/A	-5	N/A
12/31/2014	6	-5	N/A	-2	N/A
12/31/2013	6	-6	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RGNX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: RGNX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: RGNX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: RGNXDie Einnahmen des Unternehmens (36.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: RGNXDie Einnahmen des Unternehmens (36.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RGNX wird voraussichtlich in 3 Jahren unrentabel sein.

REGENXBIO Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 21%, EPS upgraded

REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Consensus revenue estimates fall by 27%

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Price target increased by 7.3% to US$38.55

Consensus EPS estimates fall by 21%

Recent updates

REGENXBIO Inc. Announces Chief Financial Officer Changes

Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?

Independent Director exercised options and sold US$78k worth of stock

REGENXBIO Inc. Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect

Consensus revenue estimates decrease by 21%, EPS upgraded

Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder

REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

New major risk - Financial position

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

REGENXBIO Inc. Reports New, Positive Interim Safety and Efficacy Data in Phase I/II AFFINITY DUCHENNE Trial of RGX-202 in Patients with Duchenne Muscular Dystrophy Ages 1 to 11 Years Old

Chairman exercised options and sold US$279k worth of stock

Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price

REGENXBIO Inc. Announces Expansion of Affinity Duchenne Trial to Include a New Cohort of Younger Patients

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

REGENXBIO Inc. Announces Chief Executive Officer Changes

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

President notifies of intention to sell stock

Consensus revenue estimates fall by 27%

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

First quarter 2024 earnings: EPS and revenues miss analyst expectations

REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

President exercised options and sold US$216k worth of stock

REGENXBIO Inc., Annual General Meeting, May 31, 2024

REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

President exercised options and sold US$272k worth of stock

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

REGENXBIO Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

REGENXBIO Inc. has completed a Follow-on Equity Offering in the amount of $140.000848 million.

Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

REGENXBIO Inc. has completed a Follow-on Equity Offering in the amount of $140.000848 million.

Price target increased by 7.3% to US$38.55

Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

REGENXBIO Inc. Announces New Interim Safety and Efficacy Data from Duchenne Trial

Consensus EPS estimates fall by 21%

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

President exercised options and sold US$195k worth of stock

REGENXBIO Inc. Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips

President notifies of intention to sell stock

REGENXBIO Inc. Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

Consensus revenue estimates fall by 16%

Executive VP & Chief Medical Officer notifies of intention to sell stock

President notifies of intention to sell stock

There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues

Price target decreased by 10% to US$36.40

REGENXBIO Inc. Announces Dose Escalation in AFFINITY Duchenne®? Trial

Consensus EPS estimates upgraded to US$4.84 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

REGENXBIO Inc. Presents Positive One Year Data from Phase II ALTUDE®? Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

Vitreous Retina Macula Consultants of New York Announces Participation in Wet AMD Study in Collaboration with Regenxbio

REGENXBIO Inc. Announces Additional Interim Safety Data and Initial Efficacy Data from the Phase I/II AFFINITY Duchenne Trial of RGX-202

REGENXBIO Inc. Announces Initial Clinical Data from First Pediatric CLN2 Patient Dosed with RGX-181

Consensus EPS estimates fall by 19%

Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023

Consensus EPS estimates upgraded to US$4.26 loss

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%

Consensus revenue estimates fall by 21%

Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be

Full year 2022 earnings released: US$6.50 loss per share (vs US$3.01 profit in FY 2021)

REGENXBIO Inc. Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process

REGENXBIO Inc. Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, Is Active and Recruiting Patients